@article{10.11648/j.crj.20241203.11,
  author = {Bwede Eugene Samuel and Amos Dangana and Taofeeq Oduola and Chinedu Onwuchekwa and Yinka Oyeniyi and Mangpin Leviticus Dansura and Villeng Felix Gagari and Mercy Ekene Mobi and Ezeama Juliet Chika and Adesuyi Ayodeji Omoare and Muhammad Sani Usman and Agwu Enoch Ojenya and Nyiri Miriam Gyang and Chinwe Ndidi Ugwu and Idris Nasir Abdullahi},
  title = {Glucose-6-Phosphate Dehydrogenase Levels and Oxidative Stress Markers Among Cancer Patients in Jos, Nigeria
},
  journal = {Cancer Research Journal},
  volume = {12},
  number = {3},
  pages = {36-43},
  doi = {10.11648/j.crj.20241203.11},
  url = {https://doi.org/10.11648/j.crj.20241203.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.crj.20241203.11},
  abstract = {Glucose-6-phosphate dehydrogenase (G6PD) is a sensitive cytosolic antioxidant enzyme that could be associated with carcinogenesis. Hence, its plasma levels are a good indicator to monitor cancer-induced cellular stress. This study aimed to determine the correlation between Glucose-6-phosphate dehydrogenase and oxidative stress markers among cancer patients in Jos, Nigeria. This case-control study involved 100 subjects (60 cancer patients and 40 healthy control subjects). Their blood samples were collected to measure the levels of G6PD and oxidative stress markers (malondialdehyde, total plasma peroxide, total antioxidant potential, and oxidative stress indices). Twenty-four (40.0%) of the cancer patients were G6PD deficient. Of this, 13 (54.2%) were females G6PD. Of the G6PD deficient cancer patients, 11(45.8%) were male, conversely, 16 (44.4%) of the cancer subjects who had normal G6PD were males. Of the cancer patients, 26.7%; 13.3%, 11.7 % and 10% had prostate, breast cancer, chronic lymphocytic leukemia (CLL), and hepatocellular carcinoma (HCC), respectively were the most frequent. There was no significant association between G6PD deficiency and cancer (X2=0.025, p=0.804). Among G6PD deficiency cancer patients, the oxidative stress markers were significantly (p0.05) higher compared to the control group. These findings showed that relatively more of the cancer patients had normal G6PD status even in increased cellular oxidative stress which could be due to host genetic factors. This suggests the need for further experiments on molecular characterization of mechanisms responsible for the findings.
},
 year = {2024}
}

Copy | Download

TY  - JOUR
T1  - Glucose-6-Phosphate Dehydrogenase Levels and Oxidative Stress Markers Among Cancer Patients in Jos, Nigeria

AU  - Bwede Eugene Samuel
AU  - Amos Dangana
AU  - Taofeeq Oduola
AU  - Chinedu Onwuchekwa
AU  - Yinka Oyeniyi
AU  - Mangpin Leviticus Dansura
AU  - Villeng Felix Gagari
AU  - Mercy Ekene Mobi
AU  - Ezeama Juliet Chika
AU  - Adesuyi Ayodeji Omoare
AU  - Muhammad Sani Usman
AU  - Agwu Enoch Ojenya
AU  - Nyiri Miriam Gyang
AU  - Chinwe Ndidi Ugwu
AU  - Idris Nasir Abdullahi
Y1  - 2024/07/04
PY  - 2024
N1  - https://doi.org/10.11648/j.crj.20241203.11
DO  - 10.11648/j.crj.20241203.11
T2  - Cancer Research Journal
JF  - Cancer Research Journal
JO  - Cancer Research Journal
SP  - 36
EP  - 43
PB  - Science Publishing Group
SN  - 2330-8214
UR  - https://doi.org/10.11648/j.crj.20241203.11
AB  - Glucose-6-phosphate dehydrogenase (G6PD) is a sensitive cytosolic antioxidant enzyme that could be associated with carcinogenesis. Hence, its plasma levels are a good indicator to monitor cancer-induced cellular stress. This study aimed to determine the correlation between Glucose-6-phosphate dehydrogenase and oxidative stress markers among cancer patients in Jos, Nigeria. This case-control study involved 100 subjects (60 cancer patients and 40 healthy control subjects). Their blood samples were collected to measure the levels of G6PD and oxidative stress markers (malondialdehyde, total plasma peroxide, total antioxidant potential, and oxidative stress indices). Twenty-four (40.0%) of the cancer patients were G6PD deficient. Of this, 13 (54.2%) were females G6PD. Of the G6PD deficient cancer patients, 11(45.8%) were male, conversely, 16 (44.4%) of the cancer subjects who had normal G6PD were males. Of the cancer patients, 26.7%; 13.3%, 11.7 % and 10% had prostate, breast cancer, chronic lymphocytic leukemia (CLL), and hepatocellular carcinoma (HCC), respectively were the most frequent. There was no significant association between G6PD deficiency and cancer (X2=0.025, p=0.804). Among G6PD deficiency cancer patients, the oxidative stress markers were significantly (p0.05) higher compared to the control group. These findings showed that relatively more of the cancer patients had normal G6PD status even in increased cellular oxidative stress which could be due to host genetic factors. This suggests the need for further experiments on molecular characterization of mechanisms responsible for the findings.

VL  - 12
IS  - 3
ER  - 

Copy | Download